Abstract Number: 3110 • 2015 ACR/ARHP Annual Meeting
In the Multicenter Randomized Controlled Rotation or Change Trial, a Non-TNF Targeted Therapy Has a Higher Efficacy Than a Second Anti-TNF at 3, 6 and 12 Months
Background/Purpose: As many as one third of patients show insufficient response to their first TNF inhibitor (TNF-insufficient response, TNF-IR). The lack of efficacy of one…Abstract Number: 3111 • 2015 ACR/ARHP Annual Meeting
Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α (GM–CSFR-α) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: Modulating macrophage function through GM–CSF is a novel therapeutic approach for RA. Mavrilimumab, a fully human monoclonal antibody, which targets GM–CSFR-α, has demonstrated efficacy…Abstract Number: 3112 • 2015 ACR/ARHP Annual Meeting
Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
Background/Purpose: Treatment with biologics can elicit unwanted immune responses such as antidrug antibodies (ADA), which may decrease their clinical efficacy and increase adverse events. However,…Abstract Number: 3113 • 2015 ACR/ARHP Annual Meeting
Interest of Assessing Anti-Drug Antibodies for the Choice Between a Second Anti-TNF and a Non-TNF-Targeted Biologic in Patients with Inadequate Response to a First Anti-TNF : Results from the Randomized Controlled Trial « Rotation or Change »
Background/Purpose: Anti-drug antibodies (ADAs) might result in loss of efficacy to anti-TNF. The impact of ADAs to a 1st anti-TNF on subsequent response to a…Abstract Number: 3114 • 2015 ACR/ARHP Annual Meeting
Immunogenicity of Subcutaneous and Intravenous Tocilizumab As Monotherapy or in Combination with Dmards
Background/Purpose: Intravenous (IV) and subcutaneous (SC) formulations of tocilizumab (TCZ) are available for treatment of adult RA based upon the efficacy and safety outcomes of…Abstract Number: 3115 • 2015 ACR/ARHP Annual Meeting
Autoantibodies of the IgA Type a Link Between the Gut and the Anti-TNF Therapy Response in Rheumatoid Arthritis Patients Analysed in Two Clinical Trials
Background/Purpose: So far no mechanism for non response to biologicals targeting TNFα has been described despite one third of rheumatoid arthritis patients treated are non-responders.…Abstract Number: 3116 • 2015 ACR/ARHP Annual Meeting
High Level of Inflammation Predicts the Development of Diabetes Mellitus in Patients with Psoriatic Arthritis
Background/Purpose: To estimate trends in the prevalence of diabetes mellitus (DM) in patients with psoriatic arthritis (PsA) in comparison to the general population in Ontario,…Abstract Number: 3117 • 2015 ACR/ARHP Annual Meeting
Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study
Background/Purpose: Cardiovascular risk in patients with psoriatic disease is partly attributed to the high prevalence of traditional cardiovascular risk factors in these patients. This study…Abstract Number: 3118 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients By Extent of Body Surface Area Affected By Psoriasis: Results from Corrona Registry
Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis that is commonly comorbid with the skin condition, psoriasis. A major contributor to the severity…Abstract Number: 3119 • 2015 ACR/ARHP Annual Meeting
The Risk of Venous Thromboembolism in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Background/Purpose: Venous thromboembolism (VTE), the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially deadly medical problem with…Abstract Number: 3120 • 2015 ACR/ARHP Annual Meeting
The Prevalence, Incidence and Management of Hypertension, Diabetes and Hyperlipidemia in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis (RA) are associated with an increased risk for cardiovascular disease (CVD). While management of traditional CVD risk…Abstract Number: 3121 • 2015 ACR/ARHP Annual Meeting
Gender Differences in Patient Reported Outcomes (PROs) in Psoriatic Arthritis
Background/Purpose: Gender is an important patient characteristic that may potentially be used to predict clinical presentation, disease progression and therapeutic response. In recent studies, women…Abstract Number: 3122 • 2015 ACR/ARHP Annual Meeting
A Longitudinal Analysis of Change in Lupus Nephritis in an International Inception Cohort Using a Multistate Markov Model Approach
Background/Purpose: Patients with lupus nephritis (LN) may have improvement or deterioration in renal status over time. To capture bidirectional change we used a reversible multistate…Abstract Number: 3123 • 2015 ACR/ARHP Annual Meeting
Evidence of Altered Blood Brain Barrier Permeability in Systemic Lupus Erythematosus Using Magnetic Resonance Imaging
Background/Purpose: Neurocognitive dysfunction is a common manifestation of childhood-onset Systemic Lupus Erythematosus (cSLE). Murine models suggest that loss of the blood-brain barrier (BBB) integrity allows…Abstract Number: 3124 • 2015 ACR/ARHP Annual Meeting
Associations of Circulating Cell-Free Micro-RNA with Vasculopathy and Vascular Events in SLE Patients
Background/Purpose: MicroRNAs (miRNAs) are small noncoding RNAs that modulate protein translation and regulate numerous immunologic and inflammatory pathways. Certain miRNA profiles have been associated with…
ACR Meeting Abstracts